Rutgers Robert Wood Johnson Medical School | Internal Medicine/Gastroenterology Division - Advanced Endoscopy Research

Research site

(Unclaimed)

Location

135 Somerset Street, Apt 1702, New Brunswick, New Jersey, United States of America

Site insights

Top conditions

Top treatments

Empagliflozin

VX-445

Sisunatovir

Acyclovir

Epeleuton

Lenabasum

BAY3427080

tranexamic acid

Elinzanetant

Nicotine

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

15 of 49 total trials

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

The purpose of the study is to learn about the safety and amount of sisunatovir in the blood of infants and children up to age 60 months. These child...

Enrolling

Respiratory Syncytial Virus Infections

Drug: Placebo

Drug: Active

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

The purpose of this clinical trial is to learn about the safety, extent of the side effects, and immune responses of the study vaccine (called varian...

Enrolling

COVID-19

SARS-CoV-2 Virus

Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose

Biological: Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose

A Study to Learn How Safe the Study Treatment BAY94-9027 is and How it Affects the Body in Previously Treated Children Aged 7 to Less Than 12 Years With Severe Hemophilia A, a Genetic Bleeding Disorder That is Caused by the Lack of a Protein Called Clotting Factor 8 (FVIII) in the Blood (Alfa-PROTECT)

Researchers are looking for a better way to treat hemophilia A. Hemophilia A is a genetic disorder where the body does not create enough of a protein...

Active, not recruiting

Prophylaxis of Bleeding

Treatment of Bleeding

Biological: Damoctocog alfa pegol (Jivi, BAY94-9027)

ALLIANCE: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve

The objective of this study is to establish the safety and effectiveness of the Edwards SAPIEN X4 Transcatheter Heart Valve (THV) in subjects with sy...

Enrolling

Aortic Stenosis, Severe

Device: SAPIEN X4 THV

Artificial Intelligence Mobile Health Trial Of A Digital Platform To Optimize GDMT Using Wearable Sensors (AIM-POWER)

The goal of this real-world, multi-center, randomized, outpatient study is to assess the effectiveness of the Biofourmis cloud based BiovitalsHF plat...

Active, not recruiting

Heart Failure

Device: BiovitalsHF

Beating Heart Mitral Valve Repair With the HARPOON™ System (RESTORE)

The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System in the treatment of patients with severe degenerative m...

Active, not recruiting

Mitral Regurgitation

Device: HARPOON™ Beating Heart Mitral Valve Repair System

Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial (CLASP II TR)

To establish the safety and effectiveness of the Edwards PASCAL Transcatheter Repair System in patients with symptomatic severe tricuspid regurgitati...

Enrolling

Tricuspid Valve Insufficiency

Tricuspid Valve Disease

Drug: Optimal Medical Therapy

Device: Edwards PASCAL System

Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD (ACTIVATE)

The purpose of this randomized, double-blind, placebo-controlled study is to assess the efficacy of BIA 28-6156 over placebo in delaying clinical mea...

Enrolling

Parkinson's Disease

Drug: Placebo

Drug: BIA 28-6156 60 mg

Pharmacokinetics, Pharmacodynamics and Safety of Epeleuton in Patients With Sickle Cell Disease

To assess the pharmacokinetics, pharmacodynamics and safety of Epeleuton capsules in adult SCD patients who are aged ≥18 years.

Enrolling

Sickle Cell Disease

Drug: Epeleuton

Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial (DTU-STEMI)

The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior t...

Enrolling

ST Elevation (STEMI) Myocardial Infarction of Anterior Wall

Device: Impella CP® placement prior to reperfusion with Primary PCI

PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR

This study objective is to establish the safety and effectiveness of the Edwards SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA Transcatheter Hea...

Enrolling

Aortic Valve Stenosis

Aortic Stenosis, Calcific

Device: SAPIEN 3 / SAPIEN 3 Ultra / SAPIEN 3 Ultra RESILIA

Prophylaxis Regimen for Hemophilia A Patients (PREDICT)

Researchers are looking for a better way to treat people who have hemophilia A. Hemophilia A is a genetic bleeding disorder that is caused by the lac...

Enrolling

Prophylaxis of Bleeding

Hemophilia A

Biological: Damoctocog alfa-pegol is a recombinant B-domain deleted human coagulation FVIII variant site specifically conjugated with a 60 kDa, branched (30 kDa each) polyethylene glycol (PEG).

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection (Tailwind)

A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 a...

Enrolling

Lung Infection

Non-cystic Fibrosis Bronchiectasis

Other: Placebo

Biological: AP-PA02

Locations recently updated

Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects (PRIOH-1)

Randomized, open-label, multi-center, comparative trial to assess the efficacy and safety in immunocompromised subjects with acyclovir resistant or a...

Enrolling

HSV Infection

Drug: Investigator's choice

Drug: Pritelivir